Speaking Engagements
 
Email Page
HCT/P: FDA’s Newest Regulatory Battleground
February 25, 2015

Axinn Counsel Stacie Ropka presented at a webinar entitled, “HCT/P: FDA’s Newest Regulatory Battleground.” She provided an exclusive analysis of the FDA oversight of HCT/Ps with a focus on what the draft guidelines mean to manufacturers.

Click here for additional information.